We're constructive on GLOO here because the market is treating the July offering like a verdict on the business when it looks more like a financing bridge into a near-term profitability turn. Management just raised full-year revenue guidance to $195 million, reiterated a path to adjusted EBITDA breakeven in Q3 2026 and profitability in Q4 2026, and directors plus the CEO indicated interest in buying at least $6.0 million in the offering. That combination matters more than the dilution headline. At $2.95 with a market cap of just $61.34 million, the stock is being priced like the turnaround has already failed.
The cleanest bull point is that operating momentum has not rolled over. Q1 2026 revenue reached $41.5 million, up 238% year over year, and full-year guidance was raised to $195 million. Even the broader trailing numbers still show 307.7% revenue growth, which is not what a dying software story looks like. When a company is still posting triple-digit growth and keeping a near-term breakeven target intact, the right question is whether the capital raise extends the runway to that inflection rather than whether dilution exists at all.
Valuation is where the disconnect gets hard to ignore. GLOO trades at just 0.50x sales, and the Valuation component of the TickerSpark Score sits at 80 even with the stock down 47.1% year to date and underperforming the technology sector by 75.9 percentage points. That kind of compression usually shows up in businesses with shrinking revenue or a broken balance sheet. Instead, GLOO carries a Financial Health score of 64 and is raising roughly $28.2 million in net proceeds from the 7.0 million share offering, with the potential to reach $32.5 million if the underwriters' option is fully exercised. For a company this small, that is meaningful balance-sheet reinforcement ahead of the exact quarters management says should bring breakeven and profitability.
The insider signal is the piece that makes this setup more than a generic cheap-stock argument. Recent filings show 1.85 million shares bought across three insider transactions worth $6.00 million, led by CEO Scott Beck, director Derek Green, and director Pat Gelsinger. The important nuance is that these were tied to the offering rather than classic open-market accumulation, so they should not be oversold. Even so, insiders stepping into a dilutive deal with real size tells us they are willing to fund the bridge themselves while still publicly standing behind the profitability timeline.
The obvious pushback is that the fundamentals are still ugly on the surface. Operating margin is negative 84.6%, net margin is negative 119.1%, EPS growth is down 67.4% year over year, and the company has beaten consensus in only two of its last five reported quarters. The chart is also a mess: RSI is 23.1, the stock is below both its 20-day and 50-day moving averages, and it just printed near its 52-week low of $2.94. None of that is the profile of a clean momentum long.
The dilution argument is real too. The offering was initially framed around an assumed $4.44 price and later priced at $3.25, which is exactly the kind of discount that tells you demand needed help. Still, that is why the insider participation matters. If management were quietly backing away from the story, this would read like a rescue financing. Instead, the company is raising capital while reaffirming Q3 breakeven and Q4 profitability, and the people closest to the numbers are participating.
That leaves GLOO as a speculative buy for investors who can handle volatility and care more about the next operating checkpoint than the next two trading sessions. We would focus less on the ugly tape and more on whether the next quarterly update keeps the $195 million revenue path and the Q3/Q4 profitability bridge intact. If those guideposts hold, today's 0.50x sales multiple looks too depressed for a company still growing this fast.
What would change our mind is simple: a walk-back of the breakeven timeline or a material miss against that raised revenue outlook. Until then, the dilution debate looks overdone relative to the stronger signal that insiders are willing to add capital alongside the raise. This is not a widows-and-orphans stock, but the contrarian setup is real and we think the market has become too pessimistic too early.
